Integrated HIV Prevention and HCV Care for PWID
- Conditions
- HIV PreventionIntravenous Drug UsageHCVOpioid Use
- Registration Number
- NCT03981445
- Lead Sponsor
- Columbia University
- Brief Summary
The objective of this study is to compare and evaluate two strategies of delivering PrEP and Hepatitis C Virus (HCV) treatment to people who inject drugs to determine the best method of providing care. Participants will be randomized to one of two treatment arms: on-site integrated care or off-site referral to specialized care.
- Detailed Description
The first strategy, the on-site integrated care model, provides opioid agonist therapy (OAT) clinics and harm reduction sites/syringe access programs (SAP) with the tools to offer HIV prevention and HCV treatment on-site. The second strategy, the off-site referrals to specialized care model, connects people who are at risk for contracting HIV with patient navigators who help them access available HIV prevention care and, if necessary, HCV treatment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 446
Individuals must meet the following criteria to be eligible to participate in the RCT:
- be 18-64 years of age
- report injection drug use in the past 6-months
- be HIV negative
- provide informed consent
- complete a medical release form
- report living in the vicinity and being able to return for follow-up over 18-months
- be willing to use a medically acceptable form of contraception throughout the study duration (for women of childbearing potential)
- be able to communicate in English or French (site dependent)
- be receiving services at an opioid agonist therapy clinic or a syringe access program
Individuals must meet the following criteria to be eligible to participate in the qualitative interview:
- have completed the first 6 months of RCT follow up (RCT participant interviews);
- provide informed consent;
- have contributed to assessments/interviews, intervention and/or treatment follow-ups (staff interviews).
Individuals will be excluded from the RCT if they:
- have any disabling medical conditions as assessed by medical history, physical exam, vital signs, and/or laboratory assessments that in the opinion of the study physician preclude safe participation in the study or ability to provide fully informed consent.
- have any disabling mental conditions as assessed by medical history and clinical assessment that in the opinion of the study physician precludes safe participation in the study or ability to provide fully informed consent.
- have chronic renal failure
- have or have history of decompensated cirrhosis
- are HIV-positive or have symptoms of an acute HIV infection
- are pregnant (verified via pregnancy test), are planning to be pregnant during the course of the study, or breastfeeding
- have an allergy or contraindication to one of the study medications
- have prior HCV treatment failure with direct-acting antiviral (DAA) regimens (Except those who were treated, cured the virus, but were re-infected with a new virus)
- are currently on PrEP and/or HCV treatment.
- are currently in prison, in any inpatient overnight facility as required by court of law or have a pending legal action, which may prevent an individual from completing the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Sustained PrEP adherence 6 months post randomization Average proportion of Dried Blood Spots (DBS) with detectable levels of Tenofovir at 6 months
HCV cure among HCV positive strata 6-months post treatment initiation HCV cure among the HCV positive strata will be compared between both treatment arms at 12 months post randomization. HCV cure is defined as initiating HCV treatment within six (6) months of being randomized and achieving sustained viral response 12 weeks (SVR-12) post-treatment completion. HCV treatment initiation will be measured using self-report and by assessing medical/drug dispensation records. SVR-12 will be measured by testing HCV-RNA negative 12 weeks after end of HCV treatment. If a participant initiates treatment within six (6) months of randomization but does not achieve SVR-12, they will not be counted as a success. Likewise, if a participant who is randomized as HCV positive achieves SVR-12 but did not initiate treatment within 6-months of randomization, they will not be counted as a success.
- Secondary Outcome Measures
Name Time Method HCV Incidence Up to 12 months HCV status will be determined by HCV-Ab testing, and if positive, HCV-RNA testing. New incidence of HCV will be defined as an HCV-Ab positive test results in participants who were HCV-Ab negative at a previous testing visit and HCV-Ab positive/HCV-RNA positive test results in participants who had previously tested HCV-Ab positive/HCV-RNA negative
PrEP Initiation/Uptake Up to 12 months Proportion of participants who initiate PrEP before 6 months post randomization and between 6 to 12 months post randomization. PrEP initiation will be defined as record of dispensation of the first dose of TDF/FTC to a participant.
Long-term sustained PrEP Adherence Up to 12 months Proportion of participants who self-report PrEP use and achieve detectable levels of tenofovir as measured by DBS testing at 6 months and 12 months post randomization.
Behavioral disinhibition Up to 12 months Proportion of participants who increase sexual or injection risk behaviors as measured by self- report questionnaires administered at each research visit.
STI or HIV incidence Up to 12 months Sexually Transmitted Infections (STI) incidence will be defined as a positive test result for Neisseria gonorrhoeae, Chlamydia trachomatis, HIV or syphilis in participants who formerly tested negative for the STI(s).
Trial Locations
- Locations (3)
Miami
🇺🇸Miami, Florida, United States
Columbia University Irving Medical Center
🇺🇸New York, New York, United States
Montreal
🇨🇦Montreal, Quebec, Canada
Miami🇺🇸Miami, Florida, United States